Risk management options elected by women after testing positive for a BRCA mutation

• Published in: Gynecologic oncology 2014-02, Vol.132 (2), p.428-433
• Main Authors: Garcia, Christine, Wendt, Jacqueline, Lyon, Liisa, Jones, Jennifer, Littell, Ramey D, Armstrong, Mary Anne, Raine-Bennett, Tina, Powell, C. Bethan
• Format: Article
• Language: English
• Subjects: Adult; BRCA; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Breast Neoplasms - prevention & control; Breast Neoplasms - surgery; Chemoprevention; Cohort Studies; Female; Genes, BRCA1; Genes, BRCA2; Genetic Counseling; Genetic Predisposition to Disease; Guideline Adherence; Hematology, Oncology and Palliative Medicine; Hormone Replacement Therapy; Humans; Logistic Models; Mastectomy; Middle Aged; Mutation; Obstetrics and Gynecology; Ovarian cancer; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - genetics; Ovarian Neoplasms - prevention & control; Ovarian Neoplasms - surgery; Ovariectomy; Prevention; Risk Factors; Risk Management - methods
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2013.12.014

Abstract Objective To assess the uptake of risk-reducing options for the management of ovarian and breast cancer risk in BRCA mutation carriers in a large community based integrated health system in Northern California. Methods A retrospective cohort of deleterious BRCA mutation carriers (1995–2012) was evaluated for consistency with NCCN guidelines for risk reducing salpingo-oophorectomy (RRSO) by age of 35–40, risk reducing mastectomy (RRM), as well as surveillance practices, including pelvic ultrasound, CA 125, mammogram, and breast MRI. Secondary outcomes included the use of chemoprevention and hormone replacement. Results Of the 305 eligible women, 170 were BRCA 1 positive, and 135 were BRCA 2 positive. Seventy four percent underwent RRSO with only 17% under age 40, while 44% underwent RRM. The median time from the test to both RRSO and RRM was 6 months. In the first year after BRCA diagnosis, 45% underwent a pelvic ultrasound, dropping to 2.3% by year 5. In year 1, 47% had a CA 125, dropping to 2% by year 5. The number of women undergoing annual MRI and mammogram fell similarly over time. Sixteen percent of BRCA carriers used oral contraceptives (OCPs) and only one patient used tamoxifen for chemoprevention. Conclusion Uptake of RRSO in BRCA carriers in a population based health system is high, however the majority of women do not have RRSO by the NCCN recommended age. Compliance with surveillance is low and rapidly declines even 1 year out from testing. Attention needs to be focused on the earlier identification of BRCA mutation carriers with consolidated and standardized care to improve risk reduction.